Table 3. Incremental costs, health outcomes, and cost-effectiveness ICER per infection for HTC + Community ART, compared with Standard of Care, by 2060 (in 2020 USD).
| HomeTesting + Community ART vs Standard of Care | Home Testing + Clinic Care only vs Standard of Care | |
|---|---|---|
| Cost and budget impact(undiscounted) | ||
| Incremental annual programme cost, 2020–2060 | 31.6 million (UR: 21.8–40.5) | 19.5 million (UR: 16.7–22.2) |
| Incremental annual programme cost, 2020–2024 | 44.9 million (UR: 35.8–50.1) | 20.6 million (UR: 17.13–22.59) |
| Initial investment required, 2020–2024 | 14.3% (UR: 11.4–16.0) | 6.4% (UR: 5.3–7.1) |
| Health gains (undiscounted) | ||
| HIV cases averted | 957,808 (UR: 775,441–1,068,738) | 241,950 (UR: 188,780–278,365) |
| HIV deaths averted | 874,015 (UR: 703,693–965,636) | 246,258 (UR: 192,549–275,694) |
| DALYs averted | 13.0 million (UR: 10.5–14.5) | 3.7 million (UR: 2.9–4.2) |
| Cost-effectiveness (discounted 3% for both costs and health gains) | ||
| Cost per case averted | $1570 (UR: 1206–1950) | $3346 (UR: 2892–3838) |
| Cost per death averted | $1748 (UR: 1451–2013) | $3377 (UR: 3123–3730) |
| Cost per DALY averted | $102 (UR: 85–117) | $192 (UR: 181–211) |
Notes:
Costs are presented in 2020 USD. Uncertainty ranges (URs) represent the minimum and maximum for model projections using the best-fitting parameter sets.